Literature DB >> 12902892

Genetic alterations and MSI status in primary, synchronous, and metachronous tumors in a family with hereditary nonpolyposis colorectal cancer (HNPCC).

Juan J González-Aguilera1, Nargisse Nejda, Francisco J Fernández, Vicente Medina, Fernando González-Hermoso, Ysamar Barrios, Mariano Moreno Azcoita, Antonia M Fernández-Peralta.   

Abstract

In colorectal cancer, different levels of microsatellite instability (MSI) have been described: high-frequency MSI, low-frequency MSI, and stable microsatellites. MSI-H characterizes a unique clinical and pathologic phenotype known as hereditary nonpolyposis colorectal cancer syndrome (HNPCC). In this case, an increased incidence of synchronous and metachronous tumors has been reported, but there are few reports with standardized criteria of MSI in HNPCC-associated tumors. The authors attempted to establish whether tumors of the HNPCC spectrum with different levels of MSI could predict the development of metachronous carcinomas. We have examined the levels of MSI at loci frequently affected in colorectal cancers in primary, synchronous, and metachronous tumors in a family that fulfils the Amsterdam criteria for HNPCC. This family presents colorectal cancers, HNPCC-extracolonic tumors (endometrial and ureter), and tumors (breast and bladder) not described in the HNPCC spectrum. The tumors exhibited MSI-H, irrespective of their location and regardless whether they were primary, synchronous, or metachronous, with the only exception of both endometrial tumors that showed low-frequency MSI tumors (MSI-L). Our results suggest that not only colorectal tumors with MSI-H result in a potential marker for the determination of high-risk individuals for metachronous and synchronous tumors, but also MSI-L endometrial tumors might be considered as indicative of high-risk individuals.

Entities:  

Mesh:

Year:  2003        PMID: 12902892     DOI: 10.1097/01.COC.0000026601.22794.85

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

2.  Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population.

Authors:  Yuan-Zhi Zhang; Jian-Qiu Sheng; Shi-Rong Li; Hong Zhang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

3.  Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome.

Authors:  V Medina-Arana; L Delgado; L González; A Bravo; H Díaz; E Salido; D Riverol; J J González-Aguilera; A M Fernández-Peralta
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.

Authors:  A Gylling; W M Abdel-Rahman; M Juhola; K Nuorva; E Hautala; H J Järvinen; J-P Mecklin; M Aarnio; P Peltomäki
Journal:  Gut       Date:  2007-01-31       Impact factor: 23.059

5.  Pedigree and genetic analysis of a novel mutation carrier patient suffering from hereditary nonpolyposis colorectal cancer.

Authors:  Miklós Tanyi; Judith Olasz; Géza Lukács; Orsolya Csuka; László Tóth; Zoltán Szentirmay; Zsuzsa Ress; Zsolt Barta; János L Tanyi; László Damjanovich
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

6.  Double primary malignancy in colorectal cancer patients--MSI is the useful marker for predicting double primary tumors.

Authors:  H R Yun; L J Yi; Y K Cho; J H Park; Y B Cho; S H Yun; H C Kim; H K Chun; W Y Lee
Journal:  Int J Colorectal Dis       Date:  2008-09-17       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.